Methods of redirecting carbon flux and increasing C2/C3 or a C4/5/6 carbon chain length carbon-based chemical product yield in an organism, nonnaturally occurring organisms with redirected carbon flux and increased C2/C3 or C4/5/6 carbon chain length carbon-based chemical product yield and methods for using these organisms in production of C2/C3 or C4/5/6 carbon chain length carbon-based chemical products are provided.

?The invention is directed to a non-naturally occurring microbial organism comprising a first attenuation of a succinyl-CoA synthetase or transferase and at least a second attenuation of a succinyl-CoA converting enzyme or a gene encoding a succinate producing enzyme within a multi-step pathway having a net conversion of succinyl-CoA to succinate.

Methods of redirecting carbon flux and increasing C2/C3 or a C4/5/6 carbon chain length carbon-based chemical product yield in an organism, nonnaturally occurring organisms with redirected carbon flux and increased C2/C3 or C4/5/6 carbon chain length carbon-based chemical product yield and methods for using these organisms in production of C2/C3 or C4/5/6 carbon chain length carbon-based chemical products are provided.

The present application relates to a microorganism of the genus Saccharomyces producing lactic acid and a method for preparing lactic acid using the same. More specifically, the present application relates to a microorganism of the genus Saccharomyces producing lactic acid, wherein the microorganism is modified to weaken or inactivate the activity of pyruvate decarboxylase (PDC) compared to its endogenous activity, to introduce the activity of ATP-citrate lyase (ACL), and to enhance pyruvate biosynthetic pathway compared to its endogenous biosynthetic pathway, and a method for producing lactic acid using the microorganism.

The present application relates to a microorganism of the genus Saccharomyces producing lactic acid and a method for preparing lactic acid using the same. More specifically, the present application relates to a microorganism of the genus Saccharomyces producing lactic acid, wherein the microorganism is modified to weaken or inactivate the activity of pyruvate decarboxylase (PDC) compared to its endogenous activity, to introduce the activity of ATP-citrate lyase (ACL), and to enhance pyruvate biosynthetic pathway compared to its endogenous biosynthetic pathway, and a method for producing lactic acid using the microorganism.

Disclosed herein are genetically engineered hematopoietic cells, which express one or more Krebs cycle modulating polypeptides, and optionally a chimeric receptor polypeptide (e.g., an antibody-coupled T cell receptor (ACTR) polypeptide or a chimeric antigen receptor (CAR) polypeptide) capable of binding to a target antigen of interest. Also disclosed herein are uses of the engineered hematopoietic cells for inhibiting cells expressing a target antigen in a subject in need thereof.

This invention relates to the metabolic evolution of a microbial organism previously optimized for producing an organic acid in commercially significant quantities under fermentative conditions using a hexose sugar as sole source of carbon in a minimal mineral medium. As a result of this metabolic evolution, the microbial organism acquires the ability to use pentose sugars derived from cellulosic materials for its growth while retaining the original growth kinetics, the rate of organic acid production and the ability to use hexose sugars as a source of carbon. This invention also discloses the genetic change in the microorganism that confers the ability to use both the hexose and pentose sugars simultaneously in the production of commercially significant quantities of organic acids.

Disclosed herein are genetically engineered hematopoietic cells, which express one or more Krebs cycle modulating polypeptides, and optionally a chimeric receptor polypeptide (e.g., an antibody-coupled T cell receptor (ACTR) polypeptide or a chimeric antigen receptor (CAR) polypeptide) capable of binding to a target antigen of interest. Also disclosed herein are uses of the engineered hematopoietic cells for inhibiting cells expressing a target antigen in a subject in need thereof.

The invention provides an effective method for improving N-acetylglucosamine (GlcNAc) production by engineered B. subtilis Deletion of phosphoenolpyruvate carboxykinase encoding gene pckA and encoding pyruvate kinase gene pyK in recombinant GlcNAc-producing strain BSGNK-PxylA-glmS-P43-GNA1 (BSGNK) is first performed to enhance GlcNAc production, followed by overexpression of pyruvate carboxylase encoding gene pycA for facilitating cell growth. Finally, the GlcNAc production of the recombinant strain BPTS3 reached to 11.3 g/L, which was 1.84-fold of BSGNK. This method can be used for improve cellular property of engineered B. subtilis for GlcNAc production, which can be further applied to industrial production of GlcNAc.

The present invention relates to a recombinant yeast cell which is capable of producing one or more of 4-methyl itaconate, 1-methyl itaconate or 1,4-dimethyl itaconate. The invention also relates to a recombinant yeast cell which is capable of producing itaconic acid and which overexpresses: a nucleic acid encoding a polypeptide having cis-aconitate decarboxylase activity; and a nucleic acid encoding a polypeptide which catalyzes a reaction towards acetyl CoA. These recombinant yeast cells may be used in processes for the production of itaconic acid, 4-methyl itaconate, 1-methyl itaconate or 1,4-dimethyl itaconate.